Literature DB >> 23111452

Cyclin D1 polymorphism and oral cancer: a meta-analysis.

Wenjun Wang1, Yuming Zhao, Jie Yang, Bichen Lin, Haiyong Gu, Xiaoqing Cao, Lihong Ge.   

Abstract

Cyclin D1 (CCND1) plays a critical role in the G1 to S-phase cell cycle transition. Data on the association between the CCND1 A870G polymorphism and oral cancer are conflicting. To assess the relationship between the CCND1 A870G genotype and the risk of developing oral cancer, we performed a meta-analysis. We searched PubMed to December 1, 2011, for studies on this topic that had been published in the English. For each study, we calculated odds ratios (ORs) and 95 % confidence intervals (CIs), assuming the frequency of allele comparison, homozygote comparison, recessive and dominant genetic models. We then calculated pooled ORs and 95 % CIs. Seven studies were included in the meta-analysis. The CCND1 G allele was not associated with oral cancer in the frequency of allele comparison (G vs. A: OR = 0.882; 95 % CI = 0.684-1.137; p = 0.001 for heterogeneity). In the subgroup analysis, the CCND1 G allele was associated with a borderline significantly decreased risk of developing oral cancer in Asians in the frequency of allele comparison (G vs. A: OR = 0.800; 95 % CI = 0.636-1.006; p = 0.089 for heterogeneity), and the association between the GG genotype and oral cancer was significant in Asians with respect to both the homozygote comparison (GG vs. AA: OR = 0.644; 95 % CI = 0.491-0.843; p = 0.186 for heterogeneity) and the dominant genetic model (GG + AG vs. AA: OR = 0.713; 95 % CI = 0.584-0.870; p = 0.293 for heterogeneity). Our analysis provides evidence that genotypes for the CCND1 A870G polymorphism may be associated with an increased risk of developing oral cancer in the Asian population.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23111452     DOI: 10.1007/s11033-012-2025-x

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  26 in total

1.  Cyclin D1 gene polymorphism as a risk factor for oral premalignant lesions.

Authors:  Maosheng Huang; Margaret R Spitz; Jian Gu; J Jack Lee; Jie Lin; Scott M Lippman; Xifeng Wu
Journal:  Carcinogenesis       Date:  2006-04-25       Impact factor: 4.944

2.  On estimating the relation between blood group and disease.

Authors:  B WOOLF
Journal:  Ann Hum Genet       Date:  1955-06       Impact factor: 1.670

Review 3.  D-type cyclins.

Authors:  C J Sherr
Journal:  Trends Biochem Sci       Date:  1995-05       Impact factor: 13.807

4.  Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck.

Authors:  R Michalides; N van Veelen; A Hart; B Loftus; E Wientjens; A Balm
Journal:  Cancer Res       Date:  1995-03-01       Impact factor: 12.701

Review 5.  Minireview: Cyclin D1: normal and abnormal functions.

Authors:  Maofu Fu; Chenguang Wang; Zhiping Li; Toshiyuki Sakamaki; Richard G Pestell
Journal:  Endocrinology       Date:  2004-08-26       Impact factor: 4.736

Review 6.  Cyclin D1 and human neoplasia.

Authors:  R Donnellan; R Chetty
Journal:  Mol Pathol       Date:  1998-02

7.  Genetic variations in cell-cycle pathway and the risk of oral premalignant lesions.

Authors:  Yuanqing Ye; Scott M Lippman; J Jack Lee; Meng Chen; Marsha L Frazier; Margaret R Spitz; Xifeng Wu
Journal:  Cancer       Date:  2008-11-01       Impact factor: 6.860

8.  Cyclin D1 gene polymorphism as a risk factor for squamous cell carcinoma of the upper aerodigestive system in non-alcoholics.

Authors:  Ines Nobuko Nishimoto; Nidia Alice Pinheiro; Silvia Regina Rogatto; André Lopes Carvalho; Andrew J Simpson; Otávia Luisa Caballero; Luiz Paulo Kowalski
Journal:  Oral Oncol       Date:  2004-07       Impact factor: 5.337

9.  Cyclin D1 genotype in areca-associated oral squamous cell carcinoma.

Authors:  Yong-Kie Wong; Shu-Chun Lin; Che-Shoa Chang; Yu-Hsin Tseng; Chung-Ji Liu; Huey-Ching Lin; Kuo-Wei Chang
Journal:  J Oral Pathol Med       Date:  2003-05       Impact factor: 4.253

10.  Alternate splicing produces a novel cyclin D1 transcript.

Authors:  D C Betticher; N Thatcher; H J Altermatt; P Hoban; W D Ryder; J Heighway
Journal:  Oncogene       Date:  1995-09-07       Impact factor: 9.867

View more
  7 in total

1.  Over-expressed human TREK-1 inhibits CHO cell proliferation via inhibiting PKA and p38 MAPK pathways and subsequently inducing G1 arrest.

Authors:  Man Zhang; Hua-Jing Yin; Wei-Ping Wang; Jiang Li; Xiao-Liang Wang
Journal:  Acta Pharmacol Sin       Date:  2016-07-11       Impact factor: 6.150

2.  IL-1RA +2018 polymorphism and the susceptivity to pneumoconiosis: a Meta-analysis.

Authors:  Yan Zhou; Yan Kang; Zhongwei Zhang; Jin Liu
Journal:  Int J Clin Exp Med       Date:  2014-08-15

Review 3.  Hallmarks of Cancer Applied to Oral and Oropharyngeal Carcinogenesis: A Scoping Review of the Evidence Gaps Found in Published Systematic Reviews.

Authors:  Miguel Ángel González-Moles; Saman Warnakulasuriya; María López-Ansio; Pablo Ramos-García
Journal:  Cancers (Basel)       Date:  2022-08-08       Impact factor: 6.575

4.  Glutathione S-transferase T1 null genotype is associated with oral cancer susceptibility in Asian populations.

Authors:  Gang Dong; Yan Tian; Shulan Chen; Xin Xu; Jianjin Zheng; Tao Li
Journal:  Tumour Biol       Date:  2013-04-23

5.  Cyclin D1 (CCND1) G870A polymorphisms and cervical cancer susceptibility: a meta-analysis based on ten case-control studies.

Authors:  Yongfu Wu; Hui Fu; Hanbin Zhang; Haohai Huang; Miao Chen; Li Zhang; Huiling Yang; Dongyun Qin
Journal:  Tumour Biol       Date:  2014-04-16

6.  Association between Cyclin D1 polymorphism and oral cancer susceptibility: a meta-analysis.

Authors:  Lili Wang; Zhiying Wang; Xiuqiu Gao; Xin Li; Xirao Sun; Changfu Liu
Journal:  Tumour Biol       Date:  2013-11-05

7.  Cyclin D1 G870A polymorphism and risk of nasopharyngeal carcinoma: a case-control study and meta-analysis.

Authors:  Dan Liao; Yongfu Wu; Xingxiang Pu; Hua Chen; Shengqun Luo; BinBin Li; Congcong Ding; Guo-Liang Huang; Zhiwei He
Journal:  PLoS One       Date:  2014-11-19       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.